To the Editor:

In the context of the COVID-19 pandemic, institutions performing fetal echocardiography (FE) are weighing the risks and benefits of reducing the number of FE to free up resources and limit nonessential visits to hospitals and clinics. These decisions must be made rapidly, often without a solid knowledge base. As of the first week of April 2020, strategies adopted by Canadian institutions varied considerably, with some significantly scaling down the rate of FE and others maintaining the pace as before the pandemic. Here, we wish to bring forth preliminary results of the FREQUENCY (**F**etal Cardiac **Re**gistry of **Qué**bec to Improve Resource Utilizatio**n** in Fetal **C**ardiolog**y**) study, a population-based retrospective cohort study to assess the performance of prenatal congenital heart disease (CHD) screening in Québec.[@bib1] Although these results are preliminary,[@bib2] they show that scaling down the rate of FE when the second-trimester ultrasound is normal can be done without a significant increase in undetected severe CHD.

The full protocol was previously published.[@bib1] Briefly, we merged data from all FE performed in Québec from 2007 to 2015 with administrative health care data of all mother-child dyads in Québec during the same period. The cohort included 698,984 pregnancies. Of them, 14,917 (2.1%) were referred for FE owing to fetal or maternal risk factors despite a normal second-trimester ultrasound, in accordance with the scientific statement of the American Heart Association.[@bib3]

We defined moderate to severe CHD as CHD prompting termination of pregnancy, requiring cardiac intervention, or causing death at \< 12 months of age (excluding isolated septal defects). We also present results for severe CHD requiring intervention \< 1 month of life. [Table 1](#tbl1){ref-type="table"} details the number needed to screen according to the FE indication. When the second-trimester ultrasound was normal, the number needed to screen was 222 for moderate to severe CHD and 361 for severe CHD. We estimate that in the presence of a normal second-trimester ultrasound, not performing FE for maternal diabetes, family history of CHD, maternal medication, and increased nuchal translucency would reduce the number of FE by \> 40%. In our cohort, \> 95% of undetected moderate to severe CHD occurred in pregnancies without risk factors and were therefore not referred for a FE. From the perspective of the overall population of Québec, not performing a FE when the second-trimester ultrasound in normal would increase the overall number of undetected significant CHD by \< 0.8 per 10,000 pregnancies.Table 1Number needed to screen according to fetal echocardiography indicationsIndicationNo. of FEs (% of all pregnancies referred for a FE)Moderate to severe CHDSevere CHDnNo. needed to screennNo. needed to screenAll FE indications30,396 (100%)1,0732879638FE on fetuses with normal second-trimester US12,266 (40%)5522234361 Family history of CHD5646 (19%)2720915376 Maternal diabetes4031 (13%)1921212336 Medication853 (3%)24262426 Increased nuchal translucency1736 (6%)72485347Abnormal cardiac views at the second-trimester US3460 (11%)69455536Suboptimal cardiac images630 (2%)31201348FE performed before the second-trimester scan[∗](#tbl1fnlowast){ref-type="table-fn"}4387 (14%)104426964Extracardiac malformations2740 (9%)475827101All other indications6914 (23%)1434810069[^1][^2]

The COVID-19 pandemic situation is ever-changing and varies among institutions. The purpose of this letter is not to advocate for reducing the rate of FE, but to provide evidence that, if it becomes temporarily necessary, it could be done rapidly for patients with a normal second-trimester scan without increasing the number of missed severe CHD significantly. In a nonpandemic situation, balancing the pros and cons of fetal cardiology referrals is more complex. Such balancing should include CHD-specific detection rates, both FE and obstetrical ultrasound sensitivities and specificities, regional variations in detection rates, and cost-benefit analyses, all of which will be addressed in the final analyses of our study.
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[^1]: CHD, congenital heart disease; FE, fetal echocardiography; US, ultrasound.

[^2]: These FEs were referred for high-risk pregnancies but were performed before the second-trimester scan owing to various logistical reasons. They were excluded from the analysis because the results of the FE were known to the physicians performing the second-trimester scans.
